DELAFIELD, Wis. (Stockpickr) -- As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

 

Vitae Pharmaceuticals

  • Tuesday's Range: $7.83-$8.10
  • 52-Week Range: $5.41-$23.35
  • Tuesday's Volume: 21,000
  • Three-Month Average Volume: 159,920

Vitae Pharmaceuticals  (VTAE) , a biotechnology company, focuses on discovering and developing novel and small molecule drugs for diseases with unmet medical needs in the U.S. This stock is trading up 2% to $7.92 in Tuesday's trading session.

From a technical perspective, Vitae Pharmaceuticals is trending notably higher here right above some near-term support at $7.46 with lighter-than-average volume. This display of relative strength versus the overall market weakness is starting to push shares of Vitae Pharmaceuticals within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out its 20-day moving average of $8.15 to some more near-term overhead resistance levels at $8.19 to around $8.50 with high volume.

Traders should now look for long-biased trades in Vitae Pharmaceuticals as long as it's trending above some near-term support at $7.46 and then once it sustains a move or close above those breakout levels volume that hits near or above 159,920 shares. If that breakout gets started soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $9 to $9.22, or even $10 to its 50-day moving average of $10.28.

Vivus

  • Tuesday's Range: $1.10-$1.20
  • 52-Week Range: $0.94-$4.82
  • Tuesdays Volume: 889,000
  • Three-Month Average Volume: 1.30 million

Vivus  (VVUS) , a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health in the U.S. and the E.U. This stock is trading up 5.3% to $1.19 in Tuesday's trading session.

From a technical perspective, Vivus is ripping sharply higher here back above its 20-day moving average of $1.14 with decent upside volume flows. This stock has been uptrending a bit over the last few weeks, with shares moving higher from its new 52-week low of 94 cents per share to its intraday high on Tuesday of $1.20. During that uptrend, this stock has been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of Vivus within range of triggering a near-term breakout trade above some key overhead resistance levels. That trade will trigger if this stock manages to take out some key near-term overhead resistance levels at $1.20 to $1.25 with high volume.

Traders should now look for long-biased trades in Vivus as long as it's trending above some near-term support at $1.10 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.30 million shares. If that breakout gets started soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $1.40 to $1.60, or even its 50-day moving average of $1.71.

Caladrius Biosciences

  • Tuesday's Range: $1.53-$1.63
  • 52-Week Range: $1.10-$7.22
  • Tuesday's Volume: 241,000
  • Three-Month Average Volume: 480,495

Caladrius Biosciences  (CLBS) , a clinical-stage biopharmaceutical company, develops cell-based therapeutics in the U.S. This stock is trading up 3.9% to $1.60 in Tuesday's trading session.

From a technical perspective, Caladrius Biosciences is spiking sharply higher here and breaking out above some near-term overhead resistance at $1.60 with decent upside volume flows. This stock has been uptrending strong over the last few weeks, with shares moving higher from its low of $1.15 to its intraday high on Tuesday of $1.63. During that uptrend, shares of Caladrius Biosciences have been making mostly higher lows and higher highs, which is bullish technical price action. This display of relative strength on Tuesday is now starting to push this stock within range of triggering another big breakout trade. That trade will hit if this stock manages to take out its 50-day moving average of $1.67 to $1.80 with high volume.

Traders should now look for long-biased trades in Caladrius Biosciences as long as it's trending above some near-term support at $1.50 or above its 20-day moving average of $1.39 and then once it sustains a move or close above those breakout levels with volume that registers near or above 480,496 shares. If that breakout triggers soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2 to $2.12, or even $2.25 to $2.40 a share.

StemCells

  • Tuesday's Range: $0.41-$0.44
  • 52-Week Range: $0.31-$1.56
  • Tuesday's Volume: 233,000
  • Three-Month Average Volume: 1.26 million

StemCells  (STEM) , a biopharmaceutical company, researches, develops and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. This stock is trading up 6.4% to 44 cents per share in Tuesday's trading session.

From a technical perspective, StemCells is ripping higher here right off its 20-day moving average of 41 cents per share with lighter-than-average volume. This display of relative strength versus the overall market weakness is starting to push this stock within range of triggering a near-term breakout trade above some key overhead resistance levels. That breakout will hit if shares of StemCells manage to take out some key near-term overhead resistance levels at 45 cents per share to its 50-day moving average of 47 cents per share with high volume.

Traders should now look for long-biased trades in StemCells as long as it's trending above some near-term support at around 40 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.26 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at 50 to 54 cents, or even 60 cents per share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.